Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 15, 2019, covers the month of November 2019. The filing incorporates by reference a press release announcing that Redhill Biopharma Ltd., a dual-listed company, has decided to voluntarily delist from the Tel-Aviv Stock Exchange (TASE).
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose the corporate action regarding the TASE delisting and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the voluntary delisting from the Tel-Aviv Stock Exchange. No financial changes versus prior periods are reported in this specific filing.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the delisting. The filing does not provide specific guidance, outlook, or detailed risk factors beyond the implications of the delisting action itself. No unusual items or contingencies are described in the text provided.
Key Facts for Investor Verification
- Redhill Biopharma Ltd. is voluntarily delisting from the Tel-Aviv Stock Exchange.
- The company remains listed on other exchanges (implied by "dual-listed" status prior to delisting).
- The filing incorporates a press release dated November 15, 2019, as Exhibit 99.1.
- No financial performance data is included in this specific Form 6-K.